SEC Filing Summary: Imprimis Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by Imprimis Pharmaceuticals, Inc. on December 16, 2013. The filing serves as a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The registrant is incorporated in Delaware and maintains its principal executive offices in San Diego, California.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate presentation rather than a financial statement.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses on the disclosure of a management presentation.
Guidance, Outlook, and Disclosures
- Regulation FD Disclosure: The company attached a presentation (Exhibit 99.1) dated December 2013, which is used by management in meetings describing the Company.
- Legal Status of Information: The information contained in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly referenced.
- Signatory: The report was signed by Andrew R. Boll, Vice President of Accounting and Public Reporting.
Key Facts for Investor Verification
- Verify the content of the attached presentation (Exhibit 99.1) for specific business updates, as the 8-K text itself contains no operational data.
- Confirm that the presentation is not incorporated by reference into other SEC filings unless explicitly stated.
- Note the discrepancy between the request metadata (Harrow, Inc.) and the actual filing registrant (Imprimis Pharmaceuticals, Inc.).